EGFR and colorectal cancer: The treatment of colorectal cancer has improved considerably over the last decade1; while the use of targeted therapies, for example epidermal growth factor receptor inhibitors and antibodies,2 has improved the progression‐free survival for patients with advanced colorectal cancer (CRC),3 the 5‐year survival rates have only improved marginally.